^
Association details:
Biomarker:ALK positive
Cancer:Peripheral T-cell Lymphoma
Regimen:CMOP (cyclophosphamide + Duoenda (mitoxantrone liposomal) + + vincristine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1632 Combination of Mitoxantrone Hydrochloride Liposome with Cyclophosphamide, Vincristine and Prednisone (CMOP) in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial

Published date:
11/03/2022
Excerpt:
CR rate and ORR of the whole cohort were 52.0% (13/25) and 84.0% (21/25)....Median DoCR was 6.1 months (3.45-NA), median PFS was 8.8 months (7.26-10.71), and 6-month PFS rate were 78.2%....This was the first clinical study demonstrated that new combination of CMOP showed promising antitumor activity in TN-PTCL with manageable safety profiles and dose expansion study at RP2D is ongoing.
DOI:
https://doi.org/10.1182/blood-2022-163343
Trial ID: